Radiation-induced synthetic lethality: combination of poly(ADP-ribose) polymerase and RAD51 inhibitors to sensitize cells to proton irradiation

Cell Cycle. 2019 Aug;18(15):1770-1783. doi: 10.1080/15384101.2019.1632640. Epub 2019 Jun 25.

Abstract

Although improvements in radiation therapy were made over the years, radioresistance is still a major challenge. Cancer cells are often deficient for DNA repair response, a feature that is currently exploited as a new anti-cancer strategy. In this context, combination of inhibitors targeting complementary pathways is of interest to sensitize cells to radiation. In this work, we used PARP (Olaparib) and RAD51 (B02) inhibitors to radiosensitize cancer cells to proton and X-ray radiation. More particularly, Olaparib and B02 were used at concentration leading to limited cytotoxic (alone or in combination) but increasing cell death when the cells were irradiated. We showed that, although at limited concentration, Olaparib and B02 were able to radiosensitize different cancer cell lines, i.e. lung and pancreatic cancer cells. Antagonistic, additive or synergistic effects were observed and correlated to cell proliferation rate. The inhibitors enhanced persistent DNA damage, delayed apoptosis, prolonged cell cycle arrest and senescence upon irradiation. These results demonstrated that radiation-induced synthetic lethality might widen the therapeutic window, hence extending the use of PARP inhibitors to patients without BRCAness.

Keywords: PARP; RAD51; cell cycle arrest; delayed cell death; proton radiation; synthetic lethality.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • A549 Cells
  • Apoptosis / drug effects
  • Apoptosis / radiation effects
  • Boron Compounds / therapeutic use
  • Boron Compounds / toxicity
  • Cell Cycle Checkpoints / drug effects
  • Cell Cycle Checkpoints / radiation effects
  • Cell Proliferation / drug effects
  • Cell Proliferation / radiation effects
  • Cell Survival / drug effects
  • Cell Survival / radiation effects
  • DNA Damage / drug effects
  • DNA Damage / radiation effects
  • DNA Repair / drug effects
  • DNA Repair / radiation effects
  • Humans
  • Neoplasms / radiotherapy*
  • Phthalazines / therapeutic use
  • Phthalazines / toxicity
  • Piperazines / therapeutic use
  • Piperazines / toxicity
  • Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use*
  • Poly(ADP-ribose) Polymerases / metabolism
  • Protons
  • Rad51 Recombinase / antagonists & inhibitors*
  • Radiation, Ionizing
  • Radiation-Sensitizing Agents / therapeutic use*
  • Synthetic Lethal Mutations*
  • Time Factors

Substances

  • Boron Compounds
  • Phthalazines
  • Piperazines
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Protons
  • Radiation-Sensitizing Agents
  • boron oxide
  • Poly(ADP-ribose) Polymerases
  • Rad51 Recombinase
  • olaparib

Grants and funding

A.-C. Wéra was a beneficiary of a “Move-In Louvain” incoming post-doctoral fellowship, co-funded by the Marie Curie Action of the European Commission and is now supported by the Belgian Found for Scientific Research (F.R.S-FNRS). The X-ray irradiator was acquired thanks to the support of UNamur, Oncobeth and Solidarité-Espoir (CHU-UCL Namur, Sainte-Elisabeth).